The Constitution and vaccinations

World of DTC Marketing

The government has latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” With respect to children, parents do not have carte blanche. The post The Constitution and vaccinations. in the news Vaccinations & the law

Is it time for vaccination mandates?

World of DTC Marketing

29 percent of Americans said they were unlikely to get vaccinated — up from 24 percent three months earlier. Most workers do not want their own employer to require vaccination, including the vast majority of unvaccinated workers (92%). The post Is it time for vaccination mandates?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Merck pays $250M to license Moderna cancer vaccine

Bio Pharma Dive

The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release

US speeds rollout of monkeypox vaccine, treatment

Bio Pharma Dive

million doses of the Jynneos vaccine and 50,000 courses of antiviral Tpoxx to states and local governments The Biden administration next week will provide 1.8

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

Optimism on Pfizer COVID vaccine is unwarranted

World of DTC Marketing

You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised.

Profiteering off a Covid vaccine

World of DTC Marketing

SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine.

EMA adds allergic reaction warning to Novavax's COVID-19 vaccine

Bio Pharma Dive

The regulator said there have been “a few” spontaneous severe allergic reactions following administration of the vaccine, which was this week authorized in the U.S.

European regulator recommends Bavarian Nordic's vaccine for monkeypox

Bio Pharma Dive

The positive decision comes as governments aim to expand supply and quicken distribution of the vaccine to combat a widening global outbreak. Separately, the EMA backed approvals of 11 other medicines

The Covid-19 vaccine numbers game

World of DTC Marketing

SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine

GSK hires away top Pfizer vaccine scientist

Bio Pharma Dive

Philip Dormitzer, who helped Pfizer develop shots for COVID-19, RSV and influenza, will become the British pharma's head of vaccine R&D next month

Mandating vaccinations is the right decision

World of DTC Marketing

The government has the latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” We, as a nation, can not allow ignorance and stupidity to endanger us all. were for people who skipped out on getting vaccinated.

CureVac sues rival COVID-19 vaccine maker BioNTech for patent infringement

Bio Pharma Dive

The biotech, whose own efforts to develop a COVID-19 vaccine have faltered, claims its inventions were crucial to the development of BioNTech’s top-selling coronavirus shot

Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology

Bio Pharma Dive

The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology

RNA 218

FDA names new head to vaccine review office

Bio Pharma Dive

David Kaslow, the lead scientist at a global public health nonprofit, will succeed Marion Gruber, who retired last fall amid her dissent on the timing of COVID-19 vaccine boosters

GSK sets high bar with trial results for RSV vaccine

Bio Pharma Dive

With data expected for several other vaccines for the respiratory disease, GSK reported positive clinical trial results showing efficacy above 80

Covid vaccine profits and the strain on supply channels

World of DTC Marketing

SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others.

Pfizer, BioNTech bet mRNA can make a better shingles vaccine

Bio Pharma Dive

The pharma company, already partnered with BioNTech on vaccines for COVID-19 and influenza, will pay $225 million upfront to further expand its work with the German biotech

Consumers fall into three COVID-19 vaccine adoption segments

World of DTC Marketing

(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments. in the news COVID Vaccine

Vaccine from Medicago, GSK protective against COVID-19 in large study

Bio Pharma Dive

The vaccine, which Medicago plans to soon submit to Canadian regulators, would be the first of its type, though supply appears likely to be limited

J&J ends hepatitis B, HPV vaccine work with Bavarian Nordic

Bio Pharma Dive

The companies' hepatitis B program never reached clinical testing, while J&J said it would no longer develop an HPV vaccine because of the "widespread uptake" of effective shots from other companies

What DTC marketers can learn from people who refuse a COVID vaccination

World of DTC Marketing

SUMMARY: Even though the Delta variant of COVID is highly contagious, people are still choosing not to get vaccinated. Concerns about safety, fear of unknown side effects, and misinformation about COVID-19 are some reasons why people may not accept the vaccine.

Pfizer forecasts $100B in sales, fueled by COVID-19 vaccine, pill

Bio Pharma Dive

The company estimated revenue from its COVID-19 vaccine and antiviral pill Paxlovid will total $54 billion this year. Curiously, its stock fell by more than 5

Sales 241

Vaxcyte rides investor enthusiasm for early pneumococcal vaccine data

Bio Pharma Dive

Encouraging study results for a vaccine with broader coverage than Pfizer’s Prevnar 20 sent Vaxcyte’s valuation soaring and could make the company a potential takeover target

Chinese drugmaker Clover says vaccine prevents COVID-19 in large trial

Bio Pharma Dive

Positive results from Clover's Phase 3 study could mean another coronavirus vaccine option for the many countries still grappling with short supplies

Trials 262

Tracking the FDA's meeting on Pfizer's vaccine for kids

Bio Pharma Dive

Outside experts are reviewing Pfizer's application for emergency authorization of its vaccine in 5- to 11-year-olds. Follow their discussion with BioPharma Dive reporters live

mRNA can deliver universal flu vaccine, say US researchers

Pharma Phorum

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

J&J's coronavirus vaccine faces new US limits

Bio Pharma Dive

Days after the FDA strengthened safety warnings for the company's shot, a CDC panel recommended Pfizer's and Moderna's vaccines be "preferred" over J&J's

FDA grants full approval to Pfizer, BioNTech's coronavirus vaccine

Bio Pharma Dive

The long-awaited decision could strengthen the case for vaccine mandates as public health officials seek to boost rates of immunization amid a wave of COVID-19 cases

Vaccine makers move quickly to confront omicron threat

Bio Pharma Dive

Several companies, including Pfizer and Moderna, are already at work adapting their coronavirus shots to the newly identified variant, which experts worry could more readily evade vaccine protection

What DTC marketers can learn from people who refuse vaccines

World of DTC Marketing

SUMMARY : Vaccine mandates are only going to get us so far when it comes to COVID immunity. The reasons for people refusing vaccines are both safety and side effect concerns, although politics plays a big part as well. As I See It COVID Vaccine

Rethinking the rabies vaccine

Scienmag

Biology rabies Rethinking vaccineLA JOLLA—Rabies virus kills a shocking 59,000 people each year, many of them children. Some victims, especially kids, don’t realize they’ve been exposed until it is too late.

UK authorizes AstraZeneca, Oxford coronavirus vaccine, but questions linger

Bio Pharma Dive

The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it

Moderna follows Pfizer in beginning trial of omicron vaccine

Bio Pharma Dive

New data, meanwhile, help affirm the benefit of a third dose of Moderna's current vaccine The study will test a version of the biotech's COVID-19 shot that's tailored to the infectious variant.

Trials 249

Pfizer set to double weekly production of coronavirus vaccine

Bio Pharma Dive

The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday

FDA authorizes Pfizer's coronavirus vaccine for younger teens

Bio Pharma Dive

The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand

FDA starts speedy review of Takeda’s dengue vaccine

Pharma Phorum

The US regulator has started a priority, six-month review of Takeda’s dengue fever vaccine TAK-003 – tipped as a potential blockbuster product – making a decision likely in the first half of 2023. Takeda said last year that the vaccine could reach up to $1.6

Moderna data supports use of omicron booster over original vaccine

Bio Pharma Dive

New results show the two-pronged booster the FDA cleared in August sparks a stronger immune response against omicron and its subvariants than Moderna’s original shot

EU speeds approval of monkeypox vaccine as WHO declares public health emergency

Bio Pharma Dive

Vaccine maker Bavarian Nordic said it is meeting demand for its shot with production capacity of 30 million doses a year

Pfizer, BioNTech start study testing next COVID-19 vaccine

Bio Pharma Dive

The new candidate is meant to provide broader immunity over a longer period of time and is part of the companies’ strategy to stay ahead of a shifting coronavirus threat

FDA authorizes J&J's one-shot coronavirus vaccine

Bio Pharma Dive

The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time

UPS delivers coronavirus vaccines via temperature-controlled drone

Bio Pharma Dive

Drones have emerged as a speedy logistics option for time- and temperature-sensitive vaccine doses, potentially helping boost the availability of shots in rural areas

FDA advisers back Novavax's latecomer COVID-19 vaccine

Bio Pharma Dive

Outside experts debated the shot's safety profile and its efficacy versus the omicron variant but ultimately supported the vaccine, which is made using more traditional technology than Pfizer's and Moderna's